

**JAGADISHWAR**

**PHARMACEUTICAL  
WORKS LIMITED**

CIN : L24232AS1987PLC002803

**Regd. Off.:** 205, Haribol Roy Market, 2<sup>nd</sup> Floor, A.T.Road, Guwahati -781001

**Corp. Off.:** 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E\_mail ID: [jpwltd@yahoo.com](mailto:jpwltd@yahoo.com)

Phone No.: +91 9163513015

**Date: September 03, 2022**

To,  
Head- Listing & Compliance  
Metropolitan Stock Exchange of India Ltd. (MSEI),  
4th Floor, Vibgyor Towers, Plot No. C 62,  
G Block, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 098.

**Sub: Furnishing of Annual Report under regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 for the year ended 31<sup>st</sup> March, 2022.**

Dear Sir/Madam,


Please find enclosed herewith the Annual Report for the year ended on 31st March, 2022 as required under regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request you to take the same on record.

Thanking You.

Yours faithfully,

**For Jagadishwar Pharmaceutical Works Limited**

  
**Swapan Sarkar**  
**Director**  
**DIN: 05149442**



Encl.: As above

**JAGADISHWAR PHARMACEUTICAL  
WORKS LIMITED**

*34<sup>th</sup>  
ANNUAL REPORT  
2021 -2022*

# **Corporate Information**

## **BOARD OF DIRECTORS**

Mr. Swapan Sarkar (Managing Director)  
Mr. Gunodhar Ghosh  
Mr. Sandip Kumar Singh  
Ms. Tulika Paul  
Mr. Soma Ghosh

## **CHIEF FINANCIAL OFFICE**

Mr. Gunodhar Ghosh

## **COMPANY SECRETARY**

Smt. Sonam Agarwal

## **AUDITORS**

S. N. Chakrabarty & Co.  
Chartered Accountants

## **REGISTRAR & SHARE TRANSFER AGENT**

ABS Consultant Pvt. Ltd  
99, Stephen House  
4, b. B. D. Bagh (e), Kolkata – 700 001  
PH: 22201043

## **BANKERS**

HDFC BANK LTD.  
IDBI Bank Ltd.

## **REGISTERED OFFICE**

205, Haribol Roy Market  
2nd Floor, A. T. Road  
Near Saraf Building  
Guwahati – 781 001

## **CORPORATE OFFICE**

21/7, Sahapur Colony  
Ground Floor,  
Kolkata – 700 053

## **E-MAIL ADDRESS**

[jpw ltd@yahoo.com](mailto:jpw ltd@yahoo.com)

## **WEBSITE**

[www.jagadishwarpharma.com](http://www.jagadishwarpharma.com)

**JAGADISHWAR PHARMACEUTICAL WORKS LIMITED**

CIN: L24232AS1987PLC002803  
REGD. OFFICE: 205, Haribol Roy Market, 2<sup>nd</sup> Floor,  
A.T. Road, Guwahati – 781 001  
Website: www.jagadishwarpharma.com  
Email Id: jpw ltd@yahoo.com, Phone: +91 9163513015

**NOTICE**

NOTICE is hereby given that:

The 34<sup>th</sup> Annual General Meeting of the Members of Jagadishwar Pharmaceutical Works Limited will be held on Friday, 30<sup>th</sup> September, 2022 at 1.45 p.m. at the registered office of the Company to transact the following businesses: -

**ORDINARY BUSINESS**

**1. Adoption of Financial Statements for the financial year ended March 31, 2022:**

To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2022, together with the Reports of the Board of Directors and the Auditors thereon;

**2. Re-Appointment of Mr. Swapan Sarkar (holding DIN : 05149442) as a Director, liable to retire by rotation, who had offered himself for re-appointment:**

To appoint a Director in place of Mr. Swapan Sarkar (holding DIN : 05149442) who retires by rotation in term of section 152(6) of the Companies Act, 2013 and being eligible offers himself for re-appointment.

By Order of the Board  
Sd/-  
(Swapan Sarkar)  
Executive Director  
DIN: 05149442

Place: Guwahati  
Dated: 30/08/2022

**NOTES:**

1. The relative Explanatory Statement pursuant to section 102 of the Companies Act, 2013 (“Act”) setting out material facts concerning the business under item 3 of notice is annexed hereto
2. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER. Proxies, in order to be effective, must be deposited at the registered office of the company not less than 48 hours before the commencement of the meeting. A blank proxy form is attached herewith the annual report. Members are requested to note that a person can act as a proxy on behalf of Members not exceeding 50 (fifty) and holding in the aggregate not more than 10 % (ten) percent of the total share capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more than ten percent of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder.

3. Corporate Members intending to send their Authorized Representatives to attend the meeting are requested to send a Certified True Copy of the Board Resolution authorizing their Representative to attend and vote on their behalf at the Meeting.
4. Members, Proxies and Authorized Representatives are requested to bring the duly completed Attendance Slip enclosed herewith to attend the AGM.
5. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from April 1, 2022. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents for assistance in this regard.
6. As per the provisions of Section 72 of the Act, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. Members are requested to submit the said form to their DP in case the shares are held in electronic form and to RTA in case the shares are held in physical form.
7. The notice of AGM is being sent to those members/beneficial owners whose name will appear in the register of members/list of beneficiaries received from the depositories as on Friday 23<sup>rd</sup> September 2022.
8. The copy of Annual Report, notice of 34th Annual General Meeting, notice of e-voting etc. are being sent to the members through e-mail who have registered their e-mail ids with the Company/ Depository Participant (DPs)/ Company's Registrar and Transfer Agent (RTA). Members are requested to update their preferred e-mail ids with the Company/ Depository Participant (DPs)/ Company's Registrar and Transfer Agent (RTA), which will be used for the purpose of future communications.
9. Members whose e-mail ids are registered with the Company and who wish to receive printed copy of the Annual Report may send their request to the Company for the same at its registered office before the annual general meeting.
10. All the documents referred in the Notice, Annual Report and Register of Director's Shareholding are open for inspection, during the business hours, at the Registered office of the Company up to and including the date of Annual General Meeting.
11. The register of Members and Share Transfer books of the Company shall remain closed during the Book Closure period i.e. Saturday 24<sup>th</sup> September 2022 to Friday 30<sup>th</sup> September 2022 (both days inclusive).
12. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to the Company.
13. The members holding shares in the same name of same order of names under different folios are requested to send the share certificates for consolidation of such shares to the Company.
14. Shareholder seeking any information with regard to the accounts is requested to write to the Company at an early date but not later than 10 days before the scheduled date of holding of Annual General Meeting.

15. In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
16. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their Depository Participants (“DPs”) in case the shares are held by them in electronic form and with RTA in case the shares are held by them in physical form.
17. The notice of the 34th Annual General Meeting and Annual Report for the financial year 2021-22 of the Company is also been uploaded on the website of the Company i.e [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).
18. E-voting  
In compliance with the provisions of section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as substituted by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to provide its members facility to exercise their right to vote on resolutions proposed to be passed in the meeting by electronic means. The members may cast their votes using an electronic voting system from a place other than the venue of the Meeting (“remote e-voting”).
19. In terms of provisions of Section 107 of the Companies Act, 2013, since the Company is providing the facility of remote e-voting to the shareholders, there shall be no voting by show of hands at the AGM. The facility for ballot / polling paper shall be made available at the Meeting and the members attending the Meeting who have not cast their vote by remote e-voting shall be able to vote at the Meeting through ballot / polling paper.
20. The shareholders can opt for only one mode of voting i.e. remote e-voting or physical polling at the meeting. In case of voting by both the modes, vote casted through remote e-voting will be considered final and voting through physical ballot will not be considered. The members who have cast their vote by remote e-voting may also attend the Meeting.

#### **THE INSTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING:**

- Step 1** : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.
- Step 2** : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.
- (i) The voting period begins on 27<sup>th</sup> September, 2022 (9.00 A.M. IST) and ends on 29<sup>th</sup> September, 2022 (5.00 P.M. IST) During this period shareholders’ of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of 23<sup>rd</sup> September, 2022 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
  - (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
  - (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders’ resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

**Step 1:** Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting for **Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<ol style="list-style-type: none"> <li>1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or visit <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on Login icon and select New System Myeasi.</li> <li>2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly.</li> <li>3) If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></li> <li>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page or click on <a href="https://evoting.cdslindia.com/Evoting/EvotingLogin">https://evoting.cdslindia.com/Evoting/EvotingLogin</a> The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol>

<p>Individual Shareholders holding securities in demat mode with <b>NSDL Depository</b></p>	<ol style="list-style-type: none"> <li>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period.</li> <li>2) If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “Register Online for IDeAS “Portal or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.</li> </ol>
<p>Individual Shareholders (holding securities in demat mode) login through their <b>Depository Participants (DP)</b></p>	<ol style="list-style-type: none"> <li>4) You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.</li> </ol>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

<b>Login type</b>	<b>Helpdesk details</b>
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800225533
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30



**Step 2** : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(v) Login method for Remote e-Voting for **Physical shareholders and shareholders other than individual holding in Demat form.**

- 1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
  - a. For CDSL: 16 digits beneficiary ID,
  - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

	<b>For Physical shareholders and other than individual shareholders holding shares in Demat.</b>
PAN	Enter your 10digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"><li>• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.</li></ul>
Dividend Bank Details <b>OR</b> Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"><li>• If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.</li></ul>

- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:
  - (vi) After entering these details appropriately, click on “SUBMIT” tab.
  - (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant Jagadishwar Pharmaceutical Works Limited on which you choose to vote.
- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.
  - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
  - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
  - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
  - Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; [jpwltd@yahoo.com](mailto:jpwltd@yahoo.com) (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

## **PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/ DEPOSITORIES**

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to **Company/RTA email id**.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact toll free no. 1800 22 55 33

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL, ) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call at toll free no. 1800 22 55 33

Additional Information on Directors recommended for appointment / re-appointment as required under Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



### **1. Mr. Swapan Sarkar**

Name	Mr. Swapan Sarkar
DIN	05149442
Designation	Managing Director
Date of Birth	04.01.1966
Qualification & Expertise	Graduate Degree, 11years Experience in Finance
Relationship with Other Directors of the Company	Not related with any other Directors of the Company
Names of listed entities in which the person also holds the directorship and the membership of Committees of the Board	Five
Total shares held by him in the company	Nil

## ROUTE MAP



Jagadishwar Pharmaceutical Works Ltd



## JAGADISHWAR PHARMACEUTICAL WORKS LIMITED

205, Haribol Roy Market, 2nd Floor, A.T. Road,  
near Saraf Building, Guwahati, Assam 781001

## ATTENDANCE SLIP FOR THE ANNUAL GENERAL MEETING

Name	
Jointly with	
Address	
Folio No	
Full name of Proxy (if attending the Meeting )	

I/We hereby record my/our presence at the 34<sup>th</sup> Annual General Meeting of the company, to be held on Friday, September 30, 2022 at 1.45 PM at Haribol Roy Market, 2nd Floor, A.T. Road, Guwahati – 781 001.

---

Signature of the shareholder/proxy

Form No. MGT-11

PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s)	
Address	
Folio No/ Client Id	
DP ID	
E-mail Id	

I/ We, being the member(s) of Jagdishwar Pharmaceutical Works Limited, holding ..... Equity Shares of the Company, hereby appoint.

1	Name:	Address:
	Email Id:	
		Signature:
	Or failing him/her	
2	Name:	Address:
	Email Id:	
		Signature:
	Or failing him/her	
3	Name:	Address:
	Email Id:	
		Signature:
	Or failing him/her	

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at 34th Annual General Meeting of members of the Company, to be held on Friday, September 30, 2022 at 1.45 PM at Haribol Roy Market, 2nd Floor, A.T. Road, Guwahati – 781 001 and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.	Resolutions	For	Against
	Ordinary Business		
1	Adoption of Financial Statements for the financial year ended March 31, 2022:		
2	Re-Appointment of Mr. Swapan Sarkar (holding DIN : 05149442) as a Director, liable to retire by rotation, who had offered himself for re-appointment:		

Signed this ..... day of , 2022

Signature of Shareholder

Signature of Proxy holder(s)

Affix  
Revenue  
Stamp

## **JAGADISHWAR PHARMACEUTICAL WORKS LIMITED**

CIN: L24232AS1987PLC002803  
REGD. OFFICE: 205, Haribol Roy Market, 2<sup>nd</sup> Floor,  
A.T. Road, Guwahati – 781 001  
Website: www.jagadishwarpharma.com  
Email Id: jpw ltd@yahoo.com, Phone: +91 9163513015

### **DIRECTOR'S REPORT**

To,  
The Shareholders,

Your Directors have pleasure in presenting the 34<sup>th</sup> Annual Report along with the Audited Financial statements of the Company for the financial year ended 31<sup>st</sup> March, 2022.

#### **1. Financial Results:**

<b>Particulars</b>	<b>2021-22</b>	<b>2020-21</b>
Income	52.45	407.40
Expenditure	39.69	395.03
Profit/(Loss) before depreciation tax and exceptional item Exceptional item	12.76	12.37
Depreciation	---	--
Exceptional item	---	--
Profit/(Loss) before Taxation	12.76	12.37
Deferred Tax/Current tax	3.38	3.35
Profit/(Loss) After Taxation	9.38	9.02

#### **2. Business performance:**

The Company does not have divisions therefore division wise working details are not applicable. Total revenue from operations of the Company was Rs 52.45 lacs for the year ended 31<sup>st</sup> March, 2022 as against Rs. 407.40 Lacs for the year ended 31<sup>st</sup> March, 2021. During the financial year 2021-2022, the Company earned a profit after tax of Rs 9.38 Lacs as compared to Rs. 9.02 Lacs in previous year.

#### **3. Share Capital:**

The paid up equity capital as on March 31, 2022 is Rs. 29,70,01,900/- divided into 2,97,00,190 equity shares of Rs. 10/- each. During the year under review, the Company has not issued bonus shares nor issued shares with differential voting rights nor granted stock options nor sweat equity and nor buy back its own securities.

#### **4. Change in nature of Business:**

There was no change in nature of business activity during the year.

#### **5. Transfers to Reserves:**

During the year, the Company has not transferred any amount to the reserves.

**6. Material Changes and Commitments Affecting The Financial Position of the Company occurred between the end of the Financial Year of the Company to which The financial statement relate and the date of the report:**

There are no material changes and commitments affecting the financial position of the company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

**7. Dividend:**

Your Directors do not recommend any dividend for the equity shareholders for the financial year 2021-2022.

**8. Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Out-Go:**

**A) Conservation of energy:**

- (i) The steps taken or impact on conservation of energy; Nil
- (ii) The steps taken by the company for utilizing alternate sources of energy; Nil
- (iii) The capital investment on energy conservation equipment; Nil

**Note: - The Company does not have any manufacturing activities which require heavy consumption of energy. The company uses latest technology low energy consumption products in its office.**

**B) Technology absorption:**

- (i) The efforts made towards technology absorption: Nil
- (ii) The benefits derived like product improvement, cost reduction, product development or import substitution: Nil
- (iii) In case of imported technology (imported during the last three years reckoned from the beginning of the financial year): Nil
  - a) The details of technology imported: Nil
  - b) The year of import; Nil
  - c) Whether the technology been fully absorbed; Nil
  - d) If not fully absorbed, areas where absorption has not taken place, and the reasons thereof; Nil and
- (iv) The expenditure incurred on Research and Development. Nil

**Note: - In respect of the Nature of the Business of the company there was no requirement of any technology.**

**C) Foreign exchange earnings and Outgo:**

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows. -No Foreign Exchange is earned or spent by the company during the year under review.

**9. Extract of Annual Return:**

As required under Section 134(3)(a) of the Act, the extract of the Annual Return for the financial year 2021- 22 in Form MGT-9 is put up on the Company's website at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).



## **10. Directors and Key Managerial Personnel**

### **A) Changes in Directors and Key Managerial Personnel:**

- i) As per the provisions of Section 149 and 152 of the Companies Act, the shareholders at their Annual General Meeting held on 29<sup>th</sup> September, 2021 (Last years AGM) had approved the re-appointment of all existing Independent Directors of the Company for tenure of up to five consecutive years. None of the Independent Directors are liable to retire by rotation.
- ii) In accordance with section 149(7) of the Companies Act, 2013, each Independent Director has confirmed to the Company that he or she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- iii) Further, in accordance with provisions of Section 152 of the Companies Act, 2013, read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of your Company Mr. Swapan Sarkar, Director, of the Company is liable to retire by rotation at the ensuing AGM and being eligible offered himself for reappointment.
- iv) Mrs. Tulika Paul (DIN 07403891) was appointed on May 3, 2021 as Additional Director in the category of Independent Director. She has expressed her desire to be re appointed as an Independent Director not liable to retire by rotation of the company. In accordance with the provisions of section 160 (1) of the Companies Act, 2013, company has received a notice from one of the members signifying her candidature. Further, Mrs. Tulika Paul, has submitted a declaration that she meets the criteria for independence as provided in Section 149 (6) of the Act and Regulation 16 (b) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, Mrs. Tulika Paul holds a Graduate degree from Kolkata. At present she is working as a Sales Officer.
- v) Mrs. Soma Ghosh (DIN 09153111) was appointed on May 3, 2021 as Additional Director in the category of Independent Director. She has expressed her desire to be re appointed as an Independent Director not liable to retire by rotation of the company. In accordance with the provisions of section 160 (1) of the Companies Act, 2013, company has received a notice from one of the members signifying her candidature. Further, Mrs. Soma Ghosh, has submitted a declaration that she meets the criteria for independence as provided in Section 149 (6) of the Act and Regulation 16 (b) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, Mrs. Soma Ghosh holds a Graduate degree from Kolkata. At present she is working as a Marketing Officer.
- vi) Mrs. Kakali Ghosh has resigned from the post of Directorship with effect from 03/05/2021 due to personal reasons and pre-occupation with other commitments.

### **11. Independent directors' declaration :**

Each of the Independent Directors have provided a declaration in accordance with Section 149(7) of the Act, read with Rules 16 and 25(8) of the Listing Regulations, confirming that he/she meets the criteria of independence as laid out in Section 149(6) of the Act and Regulations 16(1)(b) and 25(8) of the Listing Regulations.

### **12. Deposits:**

During the year under review, your Company did not accept any deposits within the meaning of provisions of Chapter V – Acceptance of Deposits by Companies of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

### **13. Internal Control Systems and their Adequacy:**

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The scope and authority of the Internal Audit function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit function reports to the Chairman of the Audit Committee of the Board.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies at all locations of the Company. Based on the report of internal audit function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

### **14. Board and Committee Meetings:**

The Board of Directors (herein after called as “the Board”) met for 6 (Six) times during the Year under review:

<b>Sr. No.</b>	<b>Particulars</b>	<b>No. of meetings held</b>
<b>1</b>	Board meetings	<b>6</b>
<b>2</b>	Audit Committee meetings	<b>4</b>
<b>3</b>	Nomination and Remuneration Committee meeting	<b>4</b>
<b>4.</b>	Stakeholders Committee Meeting	<b>4</b>

### **15. Code of Conduct:**

The Company has laid down a code of conduct for all Board members and senior management and Independent Directors of the Company. All the Board members including independent directors and senior management personnel have affirmed compliance with the code of conduct.

### **16. Vigil Mechanism/ Whistle Blower Policy:**

The Company has a vigil mechanism named ‘JPWL’ in terms of Section 177 of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to deal with instance of fraud and mismanagement, if any, and to report concerns about unethical behavior, wrongful conduct and violation of the Company’s code of conduct or ethics policy. The details of the said policy are explained in the Corporate Governance Report and also posted on the website of the Company i.e. [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

### **17. Remuneration Policy:**

The Board has, on the recommendation of the Nomination and Remuneration Committee adopted the Remuneration Policy, which inter-alia includes policy for selection and appointment of Directors, Key Managerial Personnel, Senior Management Personnel and their remuneration. The Remuneration Policy is stated in the Corporate Governance Report.

### **18. Familiarisation Programme For Board Members:**

The Company is required to conduct the Familiarization Programme for Independent Directors (IDs), to familiarize them about the Company and their roles, rights, responsibilities in the Company. The Familiarization Programme is stated in the Corporate Governance Report forming part of this Annual Report. The details of such Familiarization Programme for directors may be referred to, at the website of the Company at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

## **19. Secretarial Standards:**

The Company has in place proper systems to ensure compliance with the provisions of the applicable Secretarial Standards issued by The Institute of Company Secretaries of India and such systems are adequate and operating effectively.

## **20. Director's Responsibility Statement:**

The directors confirm that:

- i) In the preparation of the annual accounts, the applicable accounting standards have been followed.
- ii) The directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year 2021-22 and of the **profit** of the Company for the year under review.
- iii) The directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The directors have prepared the annual accounts on a going concern basis.
- v) The directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- vi) The directors had devised proper system to ensure compliance with the provisions of all applicable laws and that such system was adequate and operating effectively.

## **21. Risk Policy:**

Business risk evaluation and management is an ongoing process within the Company as per the risk management policy established by the board. The Company understands that risk evaluation and risk mitigation is a function of the Board of the Company and the Board of Directors is fully committed to developing a sound system for identification and mitigation of applicable risks viz., systemic and non-systemic. The Board of Directors has approved a Risk Management Policy as per which the Company is in the process of identifying critical risks of various departments within the Company. Once identified, a sound mitigation system will be put in place. Further the Board is of the opinion that at present there are no material risks that may threaten the functioning of the Company.

The Company has a Risk Management framework in place to identify, assess, monitor and mitigate various risks to the business. This framework seeks to minimize adverse impact on the business objectives and enhance the Company's competitive advantage. The framework also defines the risk management approach across the enterprise at various levels. Risk Management forms an integral part of the Company's planning process. Risk Management Committee of the Board reviews the process of risk management. The details of the Committee and its terms of reference are set out in the Corporate Governance Report forming part of the Board's Report

## **22. Auditors:**

The shareholders of the Company at the 31<sup>st</sup> Annual General Meeting was held on 30<sup>th</sup> September, 2019 had appointed M/s. S. N. Chakraborty & Co., Chartered Accountants (FRN: 309080E) as the Statutory Auditors of the company to hold office for period of 5 years commencing from the conclusion of the 31<sup>st</sup> AGM till the conclusion of 36<sup>th</sup> AGM to held in the year 2024. M/s. S. N. Chakraborty & Co. Chartered Accountants (FRN: 309080E) will continue to act as auditors of the Company till financial year 2021-22.

## **23. Statutory Auditors' Observations:**

The notes on financial statements referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors Report does not contain any qualification, reservation or adverse remark.

There is no audit qualification for the year under review. Further no frauds are reported by the Auditor which falls within the purview of Section 143(12) of Companies Act, 2013.

## **24. Particulars of Contracts and Arrangements with Related Parties:**

All contracts/arrangements/transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis and are reviewed by the Audit Committee of the Board. During the year the Company has not entered into any contract/arrangement/transaction with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions. A Policy on related party transactions has been posted on the Company's website [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com)

## **25. Disclosure under section 197(12) of the companies act, 2013 and other disclosures as per rule 5 of companies (Appointment & Remuneration) rules, 2014:**

The statement containing particulars of employees as required under 197(12) of the Companies Act, 2013 read along with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is not applicable to the Company as no employees were in receipt of remuneration above the limits specified in Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

## **26. Secretarial Audit Report:**

Pursuant to provisions of section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 G Aakash & Associates, Practicing Company Secretary was appointed to conduct the Secretarial Audit of the Company for the financial year ended March 31, 2022. The Secretarial Audit Report is annexed herewith as "**Annexure A.**"

The Secretarial Auditor of the Company has given unqualified report during the year under review.

## **27. Particulars of Loans, Guarantees or Investments:**

The Company has not given any loans or guarantees covered under the provisions of section 186 of the Companies Act, 2013 during the Financial Year 2021-22.

### **28. Equity shares with differential Rights:**

The Company has not issued any equity shares with deferential voting rights.

### **29. Corporate Social Responsibility Initiatives:**

The provisions of section 135 about constitution of Corporate Social Responsibility Committee are not applicable to the Company. Hence, the company has not formed the same.

### **30. Details of Subsidiary/Joint Ventures/Associate Companies:**

The company does not have any subsidiary companies or joint venture companies or associate companies during the year under review. Also, there was no company which have become or ceased to become the subsidiaries/joint ventures/associate company (ies) during the year.

### **31. Significant and Material Orders Passed by the Regulators or Courts or Tribunals:**

During the financial year under review there were no significant and / or material orders, passed by the Regulatory/ Statutory Authorities or the Courts, which would impact the going concern status and its future operations.

### **32. Disclosure regarding issue of Employee Stock Options:**

The Company has not issued shares under employee's stock options scheme pursuant to provisions of Section 62 read with Rule 12(9) of Companies (Share Capital and Debenture) Rules, 2014.

### **33. Disclosure regarding issue of Sweat Equity Shares**

The Company has not issued sweat equity shares pursuant to provisions of Section 54 read with Rule 8 of Companies (Share Capital and Debenture) Rules, 2014 during the Financial Year.

### **34. Management Discussion and Analysis:**

Management Discussion and Analysis Report for the financial year under review as stipulated under regulation 34 of the Listing Regulations is set out in a separate Section forming part of this Report.

### **35. Corporate Governance:**

The Corporate Governance Report for Financial Year 2021 -22 as stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as 'Listing Regulations') forms part of the Annual Report. The certificate from a practicing Company Secretary on compliance(s) with the corporate governance norms forms part of the Corporate Governance Report.

### **36. Board's Response on Auditors Qualification, Reservation or Adverse Remark or disclaimer Made:**

There are no qualifications, reservations or adverse remarks made by the Statutory Auditors in their report or by the Company Secretary in Practice in the Secretarial Audit Report.

**37. Disclosures Under Sexual Harassment of Women at workplace (Prevention, Prohibition & Redressal) Act, 2013:**

The Company is committed to provide a safe & conducive work environment to its employees and has formulated 'Policy for Prevention of Sexual Harassment' to prohibit, prevent or deter any acts of sexual harassment at workplace and to provide the procedure for the redressal of complaints pertaining to sexual harassment, thereby providing a safe and healthy work environment. During the year under review, no case of sexual harassment was reported.

**38. Details of significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and company's operations in future:**

There are no significant and material orders passed by the Regulators/ Court who would impact the going concern status of the Company and its future operations.

**39. Internal Financial Controls**

The Directors had laid down internal Financial controls to be followed by the Company and such policies and procedures adopted by the Company for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records and the timely preparation of reliable Financial information. The Audit Committee evaluates the internal financial control system periodically

**40. Compliance with Secretarial Standards on Board and General meeting**

During the year under review, the Company has complied with the applicable Secretarial Standards i.e. SS-1 and SS-2, relating to "Meetings of the Board of Directors" and "General Meetings", respectively, issued by The Institute of Company Secretaries of India.

**41. Cost Auditor**

The appointment of Cost Auditor for the Company is not applicable to the Company

**42. Appreciations:**

Your Company and its Directors wish to extend their sincerest thanks to the Members of the Company, Bankers, State Government, Local Bodies, Customers, Suppliers, Executives, Staff and workers at all levels for their continuous co-operation and assistance.

By Order of the Board  
Sd/-  
(Swapan Sarkar)  
Executive Director  
DIN: 05149442

Place: Guwahati  
Dated: 30/08/2022

**Annexure A**  
**Form No. MR-3**

**SECRETARIAL AUDIT REPORT**  
**[Pursuant to section 204(1) of the Companies Act, 2013 and rule no. 9 of the Companies**  
**(Appointment and Remuneration of Managerial Personnel) Rules, 2014]**

To,  
The Members,

**Jagadishwar Pharmaceutical Works Limited**

CIN : L24232AS1987PLC002803

205, Haribol Roy Market

A.T. Road, Guwahati-781001

1. We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Jagadishwar Pharmaceutical Works Limited** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.
2. Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:
3. We have examined the books, papers, minute books, forms and returns filed and other records maintained by Jagadishwar Pharmaceutical Works Limited for the financial year ended on 31<sup>st</sup> March, 2022 according to the provisions of:
  - (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
  - (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA) and the rules made thereunder;
  - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
  - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
  - (v) The Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') viz.:
    - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
    - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
    - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
    - (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
    - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations. 2008;
    - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
    - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009: and
    - (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998.

- (vi) Other Applicable Acts,
- (a) Factories Act, 1948
  - (b) Payment Of Wages Act, 1936, and rules made thereunder,
  - (c) The Minimum Wages Act, 1948, and rules made thereunder,
  - (d) Employees' State Insurance Act, 1948, and rules made thereunder,
  - (e) The Employees' Provident Fund and Miscellaneous Provisions Act, 1952, and rules made thereunder,
  - (f) The Payment of Bonus Act, 1965, and rules made thereunder,
  - (g) Payment of Gratuity Act, 1972, and rules made thereunder,
  - (h) The Water (Prevention & Control of Pollution) Act, 1974, Read with Water (Prevention & Control of Pollution) Rules, 1975,
  - (i) Food Safety and Standards Act, 2006, and rules made thereunder.

4. We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with Metropolitan Stock Exchange of India Limited.

5. We further report that,

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

6. We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**For G Aakash & Associates  
Company Secretaries**

**Date: 27.05.2022  
Place: Haryana**

**Sd/-  
Aakash Goel  
(Prop.)  
M. No.: A57213  
CP No.: 21629  
Peer Review No.: 1685/2022  
UDIN: A057213D000404219**



## ANNEXURE – 1

To,  
The Members,  
**Jagadishwar Pharmaceutical Works Limited**

Our report of even date is to be read along with this letter.

1. It is management's responsibility to identify the Laws, Rules, Regulations, Guidelines and Directions which are applicable to the Company depending upon the industry in which it operates and to comply and maintain those records with same in letter and in spirit. Our responsibility is to express an opinion on those records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the process and practices we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management's Representation about the compliance of Laws, Rules, Regulations, Guidelines and Directions and happening events etc.
5. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For G Aakash & Associates  
Company Secretaries**

**Date: 27.05.2022  
Place: Haryana**

**Sd/-  
Aakash Goel  
(Prop.)  
M. No.: A57213  
CP No.: 21629  
Peer Review No.: 1685/2022  
UDIN: A057213D000404219**

## REPORT ON CORPORATE GOVERNANCE

Pursuant to Schedule V (C) to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended as on date.

Corporate Governance is a set of standards which aims to improve the Company's image, efficiency and effectiveness. It is the road map, which guides and directs the Board of Directors of the Company to govern the affairs of the Company in a manner most beneficial to all the Shareholders, the Creditors, the Government and the Society at large. Your Company has complied with all material aspects of the Corporate Governance Code as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A Report on the Corporate Governance compliance is furnished below:

### 1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

Corporate governance is a value-based framework to manage our Company affairs in a fair and transparent manner. As a responsible corporation, we use this framework to maintain accountability in all our affairs and employ democratic and open processes. We have evolved guidelines and best practices over the years to ensure timely and accurate disclosure of information regarding our financials, performance, and governance of the Company. The Board of Directors and the management of the Company is committed to the consistent adherence to the corporate governance code and constant review of the Board processes, practices and the Management Systems to maintain a greater degree of responsibility and accountability.

### 2. BOARD OF DIRECTORS:

The Board of Directors is entrusted with the ultimate responsibility of the management, general affairs, directions and performance of the Company. The members on the Board possess adequate experience, expertise and skills necessary to manage the affairs of the Company in the most efficient manner. The strength of Board of Directors is 5 (Five). Whose composition and category is given below:

#### A. Composition and category of directors as on March 31, 2022:

The Board comprises such numbers of non-executive, executive and Independent Directors as required under applicable legislation. The composition of board represents an optimal mix of professionalism, knowledge and experience and enables the Board to discharge its responsibilities and provide effective leadership to the business. The Board of the Company comprises of 5 (Five) Directors. The Composition of the Board of Directors is as follows:

Director	Category
Mr. Swapan Sarkar	Executive- Non-Independent Director
Mr. Sandip Kumar Singh	Non-Executive - Independent Director
Mr. Gunodhar Ghosh	Non-Executive - Non Independent Director
Ms. Soma Ghosh	Non-Executive - Independent Director
Ms. Tulika Paul	Non-Executive - Independent Director

**B. Attendance of Each Director at the meeting of the Board of directors and the last Annual General Meeting:**

Name of the Directors	No. of Board Meeting Attended	Attendance at last AGM held on September 29, 2021
Mr. Swapan Sarkar	6	Yes
Mr. Sandip Kumar Singh	6	Yes
Mr. Gunodhar Ghosh	6	Yes
Ms. Soma Ghosh	6	Yes
Ms. Tulika Paul	6	Yes

**C. Number of Other Board of Directors Or Committees in Which A Directors is a member or chairperson:**

Directors	Category	No. of other Directorship	No. of other Committee positions	
			Member	Chairman
Mr. Swapan Sarkar	Executive- Non-Independent Director	6	0	6
Mr. Sandip Kumar Singh	Non-Executive - Independent Director	6	6	0
Mr. Gunodhar Ghosh	Non-Executive – Non Independent Director	6	6	0
Ms. Soma Ghosh	Non-Executive - Independent Director	6	6	0
Ms. Tulika Paul	Non-Executive - Independent Director	6	6	0

**D. Number of Meetings of the Board of Directors held and dates on which held:**

During the year under review, the meetings of the Board of Directors were held Six (6) times on the following dates and confirm to the Regulation 17(2) of the Listing Regulations.:

- 3<sup>rd</sup> May 2021
- 26<sup>th</sup> June 2021
- 28<sup>th</sup> July 2021
- 2<sup>nd</sup> September 2021
- 12<sup>th</sup> November 2021
- 31<sup>st</sup> January 2022

**E. Disclosure of Relationships Between Directors Inter-Se:**

None of the Directors of the Company are related to each other.

**F. Separate Meetings of Independent Directors:**

As stipulated under Schedule IV to the Companies Act, 2013 and Regulation 25(3) of the Listing Regulations, a separate meeting of the Independent Directors was held. Amongst other matters they reviewed the performance of Non Independent Directors and the Board as a whole; reviewed the performance of the Chairperson of the Company, and assessed the quality, quantity and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform their duties

**G. Number of shares and convertible instruments held by Non-Executive directors:**

None of the Non- Executive Directors of the Company has Equity shares and convertible instruments

**H. Familiarization programme imparted to Independent Directors:**

Pursuant to Regulation 25(7) of the Listing Regulations, familiarization programmes were imparted to Independent Directors of the Company, on the nature of the industry and the business model of the Company, roles, rights and responsibilities of the Independent Directors and other relevant information.

The policy on familiarization programme is available at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

**I. Matrix of skill/expertise/competence of the Board of Directors:**

The role of Board of Directors is one of providing guidance and direction to the operating management of the company and laying down the framework for maintenance of high standards of governance and accountability. Since the non-executive Independent Directors are not required to involve themselves in the day to day operations and day to day strategies of running the business, no strict specific domain qualification or domain expertise can be prescribed for them. What is required is the ability to grasp the general aspects of business of the company, principles of governance and ability to articulate on matters brought to the Board etc.

**J. Independent Directors confirmation:**

Based on the disclosures received from all the independent directors and also in the opinion of the Board, the Independent Directors fulfill the conditions specified in the Companies Act, 2013 and Listing Regulations and are independent of the Management.

**3. AUDIT COMMITTEE:**

**A. Terms of reference:**

As per provisions of Section 177 of the Companies Act, 2013 and Regulation 18(3) and Schedule II - Part C to the Listing Regulations, the brief terms of reference of the Audit Committee of the Company, inter alia include-

- a) The recommendation for appointment, remuneration and terms of appointment of auditors of the Company.
- b) Review and monitor the auditor's independence and performance and effectiveness of audit process.
- c) Examination of the Financial Statement and the Auditors' Report thereon.
- d) Approval or any subsequent modification of transactions of the Company with related parties.
- e) Scrutiny of inter-corporate loans and investments.
- f) Valuation of undertakings or assets of the Company, wherever it is necessary.
- g) Evaluation of internal financial controls and risk management systems.
- h) Monitoring the end use of funds raised through public offers and related matters.

## **B. Composition, Name of Members and Chairperson:**

The composition of the Committee is in line with the provisions of Section 177 of the Companies Act, 2013 and Section 18(3) of the Listing Regulations, as detailed below:

<b>Name of Director</b>	<b>Position</b>	<b>Category</b>
Sandip Kumar Singh	Chairman	Non-Executive - Independent Director
Soma Ghosh	Member	Non-Executive - Independent Director
Tulika Paul	Member	Non-Executive - Independent Director

## **C. Meetings and attendance during the year 2021-2022:**

<b>Name of Director</b>	<b>26-06-2021</b>	<b>28-07-2021</b>	<b>12-11-2021</b>	<b>31-01-2022</b>
Sandip Kumar Singh	Yes	Yes	Yes	Yes
Soma Ghosh	Yes	Yes	Yes	Yes
Tulika Paul	Yes	Yes	Yes	Yes

The Audit Committee Meetings were also attended by the Statutory / Internal Auditors, wherever necessary.

## **4. NOMINATION AND REMUNERATION COMMITTEE**

### **A. Terms of Reference:**

The brief terms of reference are as per the provisions of Section 178 of the Companies Act, 2013 and Regulation 19(4) of the Schedule II - Part D to the Listing Regulations, inter alia include;

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and other employees;
- Formulation of criteria for evaluation of Independent Directors and the Board;
- Identifying persons who are qualified to become directors and who may be appointed in Senior Management in accordance with the criteria laid down and recommend to the Board their appointment and removal.
- Whether to extend or continue the terms of appointment of Independent Director, on the basis of the report of performance evaluation of Independent Directors.

### **B. Composition, Name of Members and Chairperson:**

The composition of the Committee is in line with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19(1) of the Listing Regulations, as detailed below:

<b>Name of Director</b>	<b>Position</b>	<b>Category</b>
Sandip Kumar Singh	Chairman	Non-Executive - Independent Director
Soma Ghosh	Member	Non-Executive - Independent Director
Tulika Paul	Member	Non-Executive - Independent Director

### C. Meetings and attendance during the year 2021-2022:

During the year under review, the Committee met on the following dates:

Name of Director	26-06-2021	28-07-2021	12-11-2021	31-01-2022
Sandip Kumar Singh	Yes	Yes	Yes	Yes
Soma Ghosh	Yes	Yes	Yes	Yes
Tulika Paul	Yes	Yes	Yes	Yes

### D. Performance evaluation criteria for independent directors:

During the year under review, the Board adopted a formal mechanism for evaluating its performance as well as that of its Committees and individual Directors, including the Chairman of the Board. The exercise was carried out through a structured evaluation process covering various aspects of the Board functioning such as composition of the Board and Committees, experience and competencies, performance of specific duties and obligations, governance issues, etc.

Separate exercise was carried out to evaluate the performance of individual Directors including the Board Chairman who were evaluated on parameters such as attendance at Board Meetings and General Meetings; participation in Board proceedings; independence and candidness shown at meetings; clarity and objectiveness in expressing views at meetings; awareness of governance code, compliance requirements, risk framework, etc.

The evaluation of the Chairman and the Non-Independent Directors were carried out by the Independent Directors. The Directors were satisfied with the outcome of the evaluation, which reflected the overall engagement of the Board and its Committees with the Company.

## 5. REMUNERATION OF DIRECTORS:

There are no pecuniary relationships or transactions of the Non-Executive Directors vis-à-vis the Company during the year other than in the nature of sitting fee, which they are entitled to as a director, as detailed below.

Name of the directors	Remuneration
Mr. Swapan Sarkar	Nil
Mr. Sandip Kumar Singh	Nil
Mr. Gunodhar Ghosh	Nil
Ms. Soma Ghosh	Nil
Ms. Tulika Paul	Nil

## 6. STAKEHOLDERS RELATIONSHIP COMMITTEE:

The composition of the Stakeholders Relationship Committee is in line with the provisions of Section 178 of the Companies Act, 2013 and Regulation 20 of the Listing Regulations, as detailed below:

Name of Director	Position	Category
Sandip Kumar Singh	Chairman	Non-Executive - Independent Director
Swapan Sarkar	Member	Executive Director
Tulika Paul	Member	Non-Executive - Independent Director

Meetings and Attendance during the year 2021-22:

During the year under review, the Committee met on the following dates:

Name of Director	26-06-2021	28-07-2021	12-11-2021	31-01-2022
Sandip Kumar Singh	Yes	Yes	Yes	Yes
Swapan Sarkar	Yes	Yes	Yes	Yes
Tulika Paul	Yes	Yes	Yes	Yes

## 7. GENERAL BODY MEETINGS:

- A. Location and time, where last three Annual General Meetings held;  
B. No. of Special Resolutions passed at the meetings:

Financial Year Ended	Date	Location of Meeting	Time
2020-21	29 <sup>th</sup> September, 2021	205, Haribol Roy Market, 2 <sup>nd</sup> Floor, A.T. Road, Guwahati 781001	1.45 P. M
2019-20	30 <sup>th</sup> September, 2020	205, Haribol Roy Market, 2 <sup>nd</sup> Floor, A.T. Road, Guwahati 781001	10.00 A. M
2018-19	30 <sup>th</sup> September, 2019	205, Haribol Roy Market, 2 <sup>nd</sup> Floor, A.T. Road, Guwahati 781001	10.00 A. M

- C. Special Resolutions passed through Postal Ballot and details of Voting Pattern during the year 2021-22:

No postal ballot was conducted during the financial year 2021-22.

- D. Passing of Special Resolutions through Postal Ballot, during the year 2021-22

Your Company may propose to pass Special Resolutions conducted through Postal Ballot, if necessary, to comply with the provisions of the Companies Act, 2013 and the Rules made thereunder

## 8. MEANS OF COMMUNICATION:

- a) The Unaudited Financial Results for every Quarter and the Annual Audited Financial Results of the Company, in the prescribed format are taken on record by the Board and are submitted to MSEI
- b) The Quarterly / Annual Results are also posted on the Company's website at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).
- c) All the Official news releases are disseminated on the website of the Company.
- d) No presentations were made to the institutional investors or to the analysts during the year under review.

## 9. GENERAL SHAREHOLDER INFORMATION:

A)	AGM: Date, time and venue	Friday, 30th September, 2022 at 1.45 p.m. 205, Haribol Roy Market, 2nd Floor, A.T. Road, Guwahati 781001
B)	Financial year	April 01, 2021 to March 31, 2022
	Adoption of Quarterly Results for the quarter ending	Date of adoption
	June 2022	On or before August 15, 2022
	September 2022	On or before November 15, 2022
	December 2022	On or before February 14, 2023
	March 2023	On or before May 31, 2023
C)	Dividend Payment Date	No dividend was declared
D)	Listing on Stock Exchanges exchange at which securities are listed Listing fee for 2021-22 have been paid in respect of MSEI.	MSEI Ltd
E)	Stock Code	JPWL
F)	Market Price Data: High., Low during each month in last financial year	There was no trading during the Year
G)	Registrar and Transfer Agents	ABS Consultant Pvt. Ltd.
H)	Share Transfer System	Demat and Physical (both)
I)	Distribution of shareholding	As per Annexure-1
J)	De-materialization of shares and liquidity	1134500 Equity share
K)	Plant Locations	NA
L)	Address for correspondence	205, Haribol Roy Market, A.T. Road, Guwahati-781001
M)	List of all credit rating obtained by the entity:	The Company was not required to obtain any Credit rating during the FY2021-22.

### Distribution of Shareholding as on 31.03.2022 (Annexure – 1)

No. of Shares	No. of shareholders	% of Total holders	No. of Shares	% of total Holdings
Upto 500	Nil	Nil	Nil	Nil
501 – 1000	Nil	Nil	Nil	Nil
1001 – 2000	3	2.56	5100	0.02
2001 – 3000	1	0.85	3000	0.01
3001 – 4000	3	2.56	11000	0.04
4001 – 5000	Nil	Nil	Nil	Nil
5001 – 10000	4	3.42	30000	0.10
10001 & Above	106	90.60	29651090	99.83
<b>TOTAL</b>	<b>117</b>	<b>100.00</b>	<b>29700190</b>	<b>100.00</b>

## 10. OTHER DISCLOSURES:

### (a) Related Party Disclosures:

During the year under review, no transaction of material nature has been entered into by the Company with its promoters, the directors or the management, or relatives, etc., that may have a potential conflict with the interests of the Company.



All related party transactions are placed before the Audit Committee as also the Board for approval. A statement giving details of the transactions entered with the related parties is placed before the Audit Committee and the Board of Directors for their approval / ratification on a quarterly basis.

The Register of Contracts containing transactions, in which directors are interested, is placed before the Audit Committee / Board regularly

The Board of Directors of the Company, on the recommendation of the Audit Committee, adopted a policy on Related Party Transactions, to regulate the transactions between the Company and its Related Parties, in compliance with the applicable provisions of the Companies Act, 2013 and the Listing Regulations. The Policy as approved by the Board is uploaded on the Company's website at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

**(b) Non-Compliances by the Company:**

There has been no instance of non-compliance by the Company on any matter related to Capital Markets during the last three Financial Years.

**(c) Establishment of Vigil Mechanism/ Whistle Blower Policy and affirmation that no personnel has been denied access to the Audit Committee:**

In accordance with the provisions of Section 177(9) of the Companies Act, 2013 and the Rules made thereunder and also Regulation 22 of the Listing Regulations, your Company has in place a vigil mechanism termed as Whistle Blower Policy, for directors and employees to report concerns about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or Ethics Policy, which also provides for adequate safeguards against victimization of director(s) / employee(s) who avail of the mechanism and also provide for direct access to the Chairman of the Audit Committee in exceptional cases.

The Whistle Blower mechanism is devised in such a manner that would enable the stakeholders, including individual employees and their representative bodies, to freely communicate their concerns about illegal or unethical practices. The Whistle Blower Policy is made available on the website of the Company at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

**(d) Compliance with Mandatory Requirements and adoption of non-mandatory requirements:**

The Company has complied with all the mandatory requirements of Corporate Governance norms as enumerated under Schedule II to the Listing Regulations.

**(e) Subsidiary Company:**

The Company does not have any Subsidiary

**(f) Disclosure of commodity price risks and commodity hedging activities: Not Applicable**

**(g) Details of utilization of funds raised through preferential allotment: Not Applicable**

**(h) Certification from Company Secretary in Practice:**

G Aakash & Associates Practicing Company Secretary, has issued a certificate confirming that none of the Directors on the Board of the Company have been debarred or disqualified

from being appointed or continuing as Directors of the Companies by the Board/Ministry of Corporate Affairs or any such statutory authority.

**(i) Details of Recommendation of Committee not accepted by the Board:**

There were no instances where the Board had not accepted any recommendation of any committee of the board which is mandatorily required, in the relevant financial year.

**(j) Total fees paid to statutory auditors for all services: Rs. 9,000/-**

**(k) Disclosures in relation to Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013.**

Number of complaints filed during the financial year	Nil
Number of complaints disposed of during the financial year	Nil
Number of complaints pending as on end of the financial year	Nil

**11. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT:**

The Company has complied with all the mandatory requirements of the Corporate Governance Report.

**12. DISCLOSURE RELATING TO ADOPTION OF DISCRETIONARY REQUIREMENTS SPECIFIED IN PART E OF SCHEDULE II:**

**(a) The Board:**

The Company has a Non- Executive Chairman and he is entitled to maintain his Chairperson's office at the Company's expenses and also allowed reimbursement of expenses incurred in performance of his duties.

**(b) Modified Opinion(s) in Audit Report: NIL**

**(c) Reporting of Internal Auditor: The Internal Auditor reports to the Audit Committee**

**13. DISCLOSURE OF COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS:**

a) The Company has complied with the Corporate Governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub regulation (2) of regulation 46(as applicable).

b) Code of Conduct for the Directors (incorporating the duties of Independent Directors) and Senior Management of the Company:

The Board of Directors had laid down a Code of Conduct applicable to all the Directors and Senior Managers of the Company. The said Code of Conduct has been posted on the website of the Company at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com).

c) Code of Conduct for prevention of Insider Trading With a view to regulate trading in securities by the directors and designated employees, the Company has adopted a code of Conduct to regulate, monitor and report trading by Insiders. The said insider trading policy has been posted on the website of the Company at [www.jagadishwarpharma.com](http://www.jagadishwarpharma.com)

**14. RECONCILIATION OF SHARE CAPITAL AUDIT:**

Karishma Sureka & Co. Practicing Company Secretary has issued quarterly reports reconciling the issued and listed capital of the Company with the aggregate of the number of shares held by shareholders in physical form and in the Depositories and the said certificates were submitted to MSEI.

**15. CEO/CFO Certification:**

As required under Schedule II - Part B to the Listing Regulations the Chief Financial Officer has furnished the necessary Certificate to the Board of Directors with respect to financial statements and Cash flow statements for the year ended March 31, 2022.

**Place: Guwahati**  
**Dated: 30/08/2022**

**By Order of the Board**  
**Sd/-**  
**(Swapan Sarkar)**  
**Executive Director**  
**DIN: 05149442**

## **CERTIFICATE ON CORPORATE GOVERNANCE REPORT**

**The Members of  
Jagadishwar Pharmaceutical Works Limited**  
CIN: L72100AS1988PLC003098

I have examined the compliance of conditions of Corporate Governance by Jagadishwar Pharmaceutical Works Limited for the year ended March 31, 2022 as per Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') for the period April 01, 2021 to March 31, 2022..

The Compliance of condition of Corporate Governance is the responsibility of the Management. Our examination was limited to the procedures and implementation thereof, adopted by the Company to ensure Compliance with the condition of Corporate Governance. It is neither an audit nor an expression of an opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors, Officers and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned clause of the Listing Regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For S. N. Chakrabarty & Co.  
Chartered Accountants  
Firm Registration No. 309080E

Sd/-  
Saurindra Nath Chakrabarty  
Proprietor

Membership No: 16230  
UDIN : 22016230AJRYHS4256  
Kolkata

## MD / CFO CERTIFICATION

(Pursuant to Regulation 17(8) read with Schedule II of SEBI  
(Listing Obligations & Disclosure Requirements) Regulations, 2015)

**To,**  
**The Board of Directors**  
**Jagadishwar Pharmaceutical Works Limited**

We have reviewed financial statements and the Cash Flow Statement for the year ended March 31, 2022 and that to the best of our knowledge and belief:

1. To the best of our knowledge and belief, we certify that:
  - a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that are misleading.
  - b) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
2. To the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls for financial reporting and have evaluated the effectiveness of internal control systems pertaining to financial reporting. We have not come across any reportable deficiencies in the design or operation of such internal controls.
4. We accept responsibility for establishing and maintaining internal controls for financial reporting and have evaluated the effectiveness of internal control systems pertaining to financial reporting. We have not come across any reportable deficiencies in the design or operation of such internal controls.

By Order of the Board  
Sd/-  
(Swapan Sarkar)  
Executive Director  
DIN: 05149442

Place: Guwahati  
Dated: 30/08/2022

## **MANAGEMENT DISCUSSION AND ANALYSIS REPORT:**

Your Directors have pleasure in presenting the Management Discussion and Analysis Report for the year ended on 31st March, 2022.

### **FORWARD-LOOKING STATEMENTS:**

This report contains forward-looking statements based on certain assumptions and expectations of future events. The Company, therefore, cannot guarantee that these assumptions and expectations are accurate or will be realised. The Company's actual results, performance or achievements can thus differ materially from those projected in any such forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events.

### **OPPORTUNITIES AND THREATS:**

The fundamental growth drivers of the country's economy as well as our company continue to remain strong despite the pressures of slowdown and inflationary conditions prevalent till recently in the nation and also globally.

The threats to the segments in which the company operates are volatility in Exchange rate, pricing pressure arising due to competition from low cost suppliers, technology up-gradation, and severe competition among competitor and newly emerging competitive nations and stricter environment laws. Further, the Indian economy is now integrated with the world economy to a very large extent and therefore vulnerable to the direct impact of such a slowdown; such an impact could adversely affect the Company's performance as well. Therefore, the company has decided to close down the manufacturing activity, concentrate on the trading, and look for other opportunities in the Export market.

### **MANAGEMENT TEAM:**

The existing management has a strong technical and management knowledge and experience in the chemical business.

Mr. Swapan Sarkar, Chairman of the Company is an entrepreneur and is having vast knowledge and expertise in handling various businesses including the business of the Company.

### **INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:**

The Company has proper and adequate internal control system commensurate with the size of the business operations geared towards achieving efficiency in its various business operations, safeguarding assets, optimum utilization of resources and compliance with statutory regulations. The management is ensuring an effective internal control system to safeguard the assets of the company. Efforts for continued improvement of internal control system are being consistently made in this regard. The company has cleared secured bank liability against assets.

### **HUMAN RESOURCES VIS-À-VIS INDUSTRIAL RELATIONS:**

The Company values and appreciates the dedication and drive with which its employees have contributed towards improved performance during the year under review. The industrial relations with staff and officers are cordial during the year under review. All issues pertaining to staff matters are resolved in harmonious and cordial manner.

**CAUTIONARY STATEMENT:**

Statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimates and expectations may be 'forward looking statements' within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates changes in the Government regulations, tax laws, and other statutes and other incidental factors.

By Order of the Board  
Sd/-  
(Swapan Sarkar)  
Executive Director  
DIN: 05149442

Place: Guwahati  
Dated: 30/08/2022

## **INDEPENDENT AUDITOR'S REPORT**

To the Members of  
**JAGADISHWAR PHARMACEUTICAL WORKS LTD.**  
**Report on the Audit of Financial Statements**

### **Opinion**

We have audited the Financial Statements of **JAGADISHWAR PHARMACEUTICAL WORKS LTD.** (“the Company”), which comprise the Balance Sheet as at 31st March 2022, and the Statement of Profit and Loss including Other Comprehensive Income, Statement of changes in Equity and Statement of Cash Flows for the year then ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information for the year ended on that date (hereinafter referred to as “Financial Statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, (“Ind AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and **Profit** and total Comprehensive Income, changes in Equity and its Cash Flows for the year ended on that date.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Emphasis of Matters**

- We draw attention to Note 44 to the Financial Statements in relation to outstanding balances of trade receivables, trade payables and loans and advances which are subject to confirmation and subsequent adjustments, if any.
- The outbreak of COVID-19 and consequent imposition of national lockdown by the Government of India to deter its impact seriously affected the economic activities and business operation of the Company. The management is believed to have considered the possible effect that may result from the pandemic on the recoverability / carrying value of the assets. Based on the current indicators of future economic conditions, the management is believed to expect to recover the carrying amounts of the assets. However, as the trend suggests future economic conditions may be subject to material changes in days ahead.



Given the uncertainty, the final impact on the company's assets in future may differ from that estimated at the date of our signing of this financial statement.

## **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matter described below to be the key audit matters to be communicated in our report.

## **Revenue Recognition**

We have identified this as an area of importance because the Company's revenue is a material item in view of adoption of Ind AS 115 "Revenue from Contracts with Customers". The application of the new revenue accounting standard involves certain key judgements relating to identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the appropriateness of the basis used to measure revenue recognised over a period and disclosures thereof.

### ***Our audit procedures included but were not limited to:***

- Evaluation of the Company's accounting principles in relation to implementation of the new revenue accounting standard;
- Created an understanding of the company's routines and internal controls associated with revenue recognition;
- Examination of a selection of transactions to ensure that they have been reported correctly according to agreements and in the correct periods;

## **Information Other than the Financial Statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Company's Annual Report, but does not include the Financial Statements and our Auditor's Report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Ind AS Financial Statements that gives a true and fair view of the financial position, financial performance, Changes in Equity and Cash Flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards prescribed under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that gives a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

### **Auditor's Responsibilities for the Audit of Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Ind AS Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Ind AS Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Ind AS Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013 we are also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Ind AS Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Ind AS Financial Statements, including the disclosures, and whether the Ind AS Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the

Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## **Report on Other Legal and Regulatory Requirements**

I. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Companies Act, 2013 and according to the information and explanations given to us and also on the basis of such checks as we considered appropriate, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

II. As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Changes in Equity and the Statements of Cash Flows dealt with by this report are in agreement with the books of account;
- d. In our opinion, the aforesaid Financial Statements comply with the Indian Accounting Standards specified under section 133 of the Act read with rule 7 of the Companies (Accounts) Rules, 2014;
- e. On the basis of the written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2022, from being appointed as a director in terms of section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The company has disclosed the impact of pending litigations on its financial position in its Financial Statements (Refer Note no. 35 of the Ind AS Financial Statements).
  - ii. The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For **S. N. Chakrabarty & Co.**  
Chartered Accountants  
Firm Regn.No.: 309080E

Place : Kolkata  
Dated : 27/05/2022

Sd/-  
Saurindra Nath Chakrabarty  
(Proprietor)  
Membership No : 016230  
UDIN: 22016230AJRYHS4256

## **“Annexure – A” to the Independent Auditors’ Report**

The Annexure referred to in our Independent Auditor’s Report to the members of **JAGADISHWAR PHARMACEUTICAL WORKS LTD.** (the Company’) on the Ind AS Financial Statements for the year ended on March 31, 2022. We report that:

- i. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.  
  
(b) The Company has a regular programme of physical verification of its fixed assets by which fixed assets are verified in a phased manner over a period of three years. In accordance with this programme, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.  
  
(c) According to information and explanation given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- ii. The inventories have been physically verified during the year by the management at regular intervals. In our opinion and according to the information and explanations given to us, no material discrepancies were noticed on physical verification.
- iii. The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013 (‘the Act’). Accordingly, paragraph 3(iii) (a), 3(iii) (b) and 3(iii) (c) of the Order is not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
- v. According to the information and explanations given to us, the Company has not accepted any deposits from the public.
- vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under section 148 (1) of the Act, and are of the opinion that prima facie the prescribed accounts and records have been made and maintained.
- vii. According to the information and explanations given to us in respect of statutory dues:
  - (a) The Company has been regular in depositing undisputed statutory dues, including Income Tax, and other statutory dues with the appropriate authorities during the year. According to the information and explanations given to us, no undisputed amounts payable in respect of the aforesaid dues were outstanding as at 31st March, 2022 for a period of more than six months from the date they became payable.
  - viii. In our opinion and according to information and explanations given by the management, we are of the opinion that the Company has not defaulted in the repayment of dues to financial institution and banks. The Company does not have any loans or borrowings from Government and has not issued any debentures.
- ix. To the best of our knowledge and belief and according to the information and explanations given to us, The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year.

- x. According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- xi. According to the information and explanations given to us, the Company has paid/provided for managerial remunerations in accordance with the requisite approvals mandated by the provisions of Sec 197 read with Schedule V to the Act.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the Ind AS Financial Statements as required by the applicable Indian accounting standards.
- xiv. According to the information and explanations given to us and based on our examination of the records, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- xv. According to the information and explanations given by the management, the Company has not entered into non-cash transactions with directors or persons connected with them as referred to in section 192 of the Companies Act, 2013. Accordingly, paragraph 3(xv) of the Order is not applicable.
- xvi. According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act 1934 are not applicable to the Company.

For **S. N. Chakrabarty & Co.**  
Chartered Accountants  
Firm Regn.No.: 309080E

Place : Kolkata  
Dated : 27/05/2022

Sd/-  
Saurindra Nath Chakrabarty  
(Proprietor)  
Membership No : 016230  
UDIN: 22016230AJRYHS4256

## **“Annexure-B” to the Independent Auditor’s Report**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **JAGADISHWAR PHARMACEUTICAL WORKS LTD.**(“the Company”) as of March 31, 2022 in conjunction with our audit of the Ind AS Financial Statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (‘ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit on Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls over Financial Reporting**

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with

authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Financial Statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **S. N. Chakrabarty & Co.**  
Chartered Accountants  
Firm Regn.No.: 309080E

Place : Kolkata  
Dated : 27/05/2022

Sd/-  
Saurindra Nath Chakrabarty  
(Proprietor)  
Membership No : 016230  
UDIN: 22016230AJRYHS4256



# Jagadishwar Pharmaceutical Works Limited

## Balance Sheet as at 31st March 2022

Particulars	Note No.	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1st April 2020 Rs.
<b>A. Assets</b>				
<b>1 Non- Current Assets</b>				
a) Property, Plant & Equipment	3	-	-	-
b) Investment Properties		-	-	-
c) Financial Assets				
i) Investments	4	12,95,94,147.54	13,02,30,881.07	17,20,00,311.55
d) Other Non- Current Assets	5	4,15,021.00	2,47,369.00	2,25,870.00
<b>Total Non Current Assets</b>		<b>13,00,09,168.54</b>	<b>13,04,78,250.07</b>	<b>17,22,26,181.55</b>
<b>2 Current Assets</b>				
a) Inventories	6	4,30,28,802.04	4,29,09,773.80	7,93,21,343.80
b) Financial Assets				
i) Cash and Cash Equivalents	7	64,70,981.65	8,30,259.57	5,62,890.07
ii) Loans	8	4,76,97,794.00	7,17,82,439.00	2,65,05,999.00
iii) Other Financial Assets		-	-	-
c) Other Current Assets	9	8,13,72,287.40	6,22,77,287.40	2,83,27,287.40
<b>Total Current Assets</b>		<b>17,85,69,865.09</b>	<b>17,77,99,759.77</b>	<b>13,47,17,520.27</b>
<b>Total Assets</b>		<b>30,85,79,033.63</b>	<b>30,82,78,009.84</b>	<b>30,69,43,701.82</b>
<b>B. Equity &amp; Liabilities</b>				
<b>1 Equity</b>				
a) Share Capital	10	29,70,01,900.00	29,70,01,900.00	29,70,01,900.00
b) Other Equity	11	1,15,67,373.63	1,12,66,349.84	99,29,301.82
<b>Total Equity</b>		<b>30,85,69,273.63</b>	<b>30,82,68,249.84</b>	<b>30,69,31,201.82</b>
<b>2 Liabilities</b>				
a) <b>Non Current Liabilities</b>				
i) Financial Liabilities		-	-	-
ii) Other Liabilities		-	-	-
<b>Total Non Current Liabilities</b>		-	-	-
b) <b>Current Liabilities</b>				
i) Financial Liabilities	12	-	-	-
ii) Other Liabilities	13	9,760.00	9,760.00	12,500.00
iii) Provisions		-	-	-
<b>Total Current Liabilities</b>		<b>9,760.00</b>	<b>9,760.00</b>	<b>12,500.00</b>
<b>Total Equity &amp; Liabilities</b>		<b>30,85,79,033.63</b>	<b>30,82,78,009.84</b>	<b>30,69,43,701.82</b>
		-	-	-
<b>Summary of significant accounting policies</b>	<b>Note 1&amp;2</b>			
See accompanying notes forming part of the financial statements				
				<b>For and on behalf of the Board</b>
In term of our report attached.				
For S. N. Chakrabarty & Co.				Sd/-
Firm Registration No. 309080E				Swapan Sarkar
Chartered Accountants				Director
				DIN: 05149442
				Sd/-
Sd/-				Sandip Kumar Singh
Saurindra Nath Chakrabarty				Director
(Proprietor)				DIN: 08443518
MRN: 016230				
				Sd/-
Place: Kolkata				Sonam Agarwal
Date : 27th May, 2022				Secretary
UDIN : 22016230AJRYH54256				ACS 55819

## Jagdishwar Pharmaceutical Works Limited

### Statement of Profit and Loss for the year ended 31 March, 2022

Particulars	Note No.	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	
<b>Income</b>				
Revenue from Operations	14	1,84,500.00	3,50,80,085.00	
Other Income	15	50,61,221.00	56,59,916.00	
<b>Total Revenue</b>		<b>52,45,721.00</b>	<b>4,07,40,001.00</b>	
<b>Expenditure</b>				
(a) Purchase		3,03,528.00	5,38,720.00	
(b) Changes in Inventories of Finished Goods	16	(1,19,028.24)	3,64,11,570.00	
(c) Depreciation and Amortisation Expense	3	-	-	
(d) Employee Benefits Expense	17	20,19,188.00	15,19,490.00	
(e) Other Expenses	18	17,65,805.92	10,32,903.00	
<b>Total Expenses</b>		<b>39,69,493.68</b>	<b>3,95,02,683.00</b>	
<b>Profit before Exceptional Items and Tax</b>		12,76,227.32	12,37,318.00	
Less: Exceptional Items		-	-	
<b>Profit/ (Loss) Before Tax</b>		<b>12,76,227.32</b>	<b>12,37,318.00</b>	
<b>Tax Expense :</b>				
(a) Tax Expense for Current Year		3,38,470.00	3,35,360.00	
(b) Tax Expense for Earlier Year		-	-	
(c) Deferred Tax Asset		-	-	
<b>Profit / (Loss) for the year</b>	<b>(A)</b>	<b>9,37,757.32</b>	<b>9,01,958.00</b>	
<b>Other Comprehensive Income</b>			-	
i. Items that will not be reclassified to profit or loss-Actuarial (Loss)/Gain	19	(6,36,733.53)	4,35,090.02	
ii. Income tax relating to items that will not be reclassified to profit or loss				
iii. Items that will be reclassified to profit or loss				
iv. Income tax relating to items that will be reclassified to profit or loss				
<b>Other Comprehensive Income</b>	<b>(B)</b>	<b>(6,36,733.53)</b>	<b>4,35,090.02</b>	
<b>Total Comprehensive Income for the Year</b>	<b>(A+B)</b>	<b>3,01,023.79</b>	<b>13,37,048.02</b>	
<b>Earnings per Equity Share of Face Value of Rs 10 each</b>				
<b>Basic and Diluted (in Rs)</b>		<b>0.38</b>	<b>0.03</b>	
<b>Summary of significant accounting policies</b>	<b>Note 1&amp;2</b>			
See accompanying notes forming part of the financial statements				
			<b>For and on behalf of the Board</b>	
In term of our report attached.				
For S. N. Chakrabarty & Co.			Sd/-	
Firm Registration No. 309080E			Swapan Sarkar	
Chartered Accountants			Director	
			DIN : 05149442	
			Sd/-	
Sd/-			Sandip Kumar Singh	
Saurindra Nath Chakrabarty			Director	
(Proprietor)			DIN : 08443518	
MRN: 016230				
			Sd/-	
Place: Kolkata			Sonam Agarwal	
Date : 27th May, 2022			Secretary	
UDIN : 22016230AJRYH54256			ACS 55819	

**Jagdishwar Pharmaceutical Works Limited**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2022**

PARTICULARS		As at 31 March, 2022 Amount (Rs.)	As at 31 March, 2021 Amount (Rs.)
<b>A.</b>	<b>Cash Flow from Operating Activities</b>		
	Net Profit/(Loss) before tax	12,76,227.32	12,37,318.00
	Adjustments for:		
	Depreciation	-	-
	Interest Income	(50,61,221.00)	(56,59,916.00)
		(50,61,221.00)	(56,59,916.00)
	<b>Operating Profit before Working Capital Changes</b>	<b>(37,84,993.68)</b>	<b>(44,22,598.00)</b>
	Adjustment for :		
	Change in Inventories	(1,19,028.24)	3,64,11,570.00
	Change in Other Current Liabilities	-	(2,740.00)
	Change in Financial Loans	2,40,84,645.00	(4,52,76,440.00)
	Change in Other Non Current Assets	-	-
	Change in Other Current Assets	(1,90,95,000.00)	(3,39,50,000.00)
	Change in Other Non Current Liabilities	-	-
		48,70,616.76	(4,28,17,610.00)
	<b>Cash Generated from Operations</b>	<b>10,85,623.08</b>	<b>(4,72,40,208.00)</b>
	- Adjustment for :-		
	Income Tax Paid	(5,06,122.00)	(3,56,859.00)
	<b>Net Cash from Operating Activities [A]</b>	<b>5,79,501.08</b>	<b>(4,75,97,067.00)</b>
<b>B.</b>	<b>Cash Flow from Investing Activities</b>		
	- Adjustment for :-		
	Non Current Financial Assets	0.00	4,22,04,520.50
	Interest Income	50,61,221.00	56,59,916.00
	<b>Net Cash used in Investing Activities [B]</b>	<b>50,61,221.00</b>	<b>4,78,64,436.50</b>
<b>C.</b>	<b>Cash Flow from Financing Activities</b>	-	-
	<b>Net Cash used in financing activities [C]</b>	-	-
	<b>Net Increase in Cash &amp; Cash equivalents</b>	<b>[A+B+C] 56,40,722.08</b>	<b>2,67,369.50</b>
	Cash & Cash equivalents as at (Opening Balance)	8,30,259.57	5,62,890.07
	Cash & Cash equivalents as at (Closing Balance)	<b>64,70,981.65</b>	<b>8,30,259.57</b>
		-	-

In term of our report attached.  
For S. N. Chakrabarty & Co.  
Firm Registration No. 309080E  
Chartered Accountants

Sd/-  
**Saurindra Nath Chakrabarty**  
(Proprietor)  
MRN: 016230

Place: Kolkata  
Date : 27th May, 2022  
UDIN : 22016230AJRYHS4256

For and on behalf of the Board

Sd/-  
**Swapan Sarkar**  
Director  
DIN: 05149442

Sd/-  
**Sandip Kumar Singh**  
Director  
DIN: 08443518

Sd/-  
**Sonam Agarwal**  
Secretary  
ACS 55819

# **Jagadishwar Pharmaceutical Works Limited**

## **Notes forming part of the financial statements**

### **1 Corporate information**

The Company Jagadishwar Pharmaceuticals Works Limited was duly incorporated on 20th November, 1987 under Companies Act, 1956 at Guwahati as a Private Limited Company and was named as Jagadishwar Pharmaceuticals Works Private Limited and is categorized as Company Limited by shares and A Non-Government Company. The Company became a Public Limited Company from 23rd January, 1989. The Company got its shares listed on Guwahati Stock Exchange earlier and the Company had to be delisted on closure of Guwahati Stock Exchange. The Company then got its shares listed at Metropolitan Stock Exchange of India Ltd. (MSEI) on 3rd July, 2015. The Company is primarily engaged in trading activities and providing interest bearing advances. .

### **2 Significant Accounting Policies**

#### **2.1 Statement of Compliance**

These financial statements have been prepared in accordance with the Indian Accounting Standards (referred to as "Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.

#### **2.2 Basis of accounting and preparation of financial statements**

These financial statements have been prepared on historical cost basis, except for certain financial instruments which are measured at fair value at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that

#### **2.3 Use of estimates**

The preparation of these financial statements in conformity with the recognition and measurement principles of Ind AS requires the management of the Company to make estimates and judgements that affect the reported balances of assets and liabilities, disclosures relating to contingent liabilities as at the date of the financial statements and the reported amounts of income and expense for the periods presented.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and future periods are affected.

The Company reviews its carrying value of investments carried at amortised cost annually, or more frequently when there is indication for impairment. If the recoverable amount is less than its carrying amount, the impairment loss is accounted for.

#### **Useful lives of property, plant and equipment**

The Company reviews the useful life of property, plant and equipment at the end of each reporting period. This reassessment may result in change in depreciation expense in future periods.

#### **Provisions and contingent liabilities**

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not

#### **Fair value measurement of financial instruments**

Financial asset included within the OCI Category are measured at each reporting date at fair value. Fair Value movements are recognised in OCI. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from OCI to statement of Profit and Loss.

#### **2.4 Revenue recognition**

Both income and expenditure items are recognized on accrual and prudent basis.

#### **2.5 Income Tax**

Current tax is determined as the amount of tax payable in respect of taxable income at applicable rate of tax for the year. The Government of India, on 20/09/2019, vide the Taxation Laws (Amendment) Ordinance 2019, inserted a new Section 115BAA in the Income Tax Act, 1961, which provides an option to the Company for paying Income Tax at reduced rates as per the provisions / conditions defined in the said section. The Company is continuing to provide for income tax at old rates, based on the available outstanding MAT credit entitlement and various exemptions and deductions available to the Company under the Income Tax Act, 1961.

#### **2.6 Earnings per share**

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

**Jagadishwar Pharmaceutical Works Limited**

**Statement of Change in Equity  
For the Year ended 31st March, 2022**

A. Equity Share Capital							
							Amount in Rs.
As at 1st April, 2020							29,70,01,900.00
Changes in Equity Share Capital during the year 2020-21							-
As at 31st March, 2021							29,70,01,900.00
Changes in Equity Share Capital during the year 2021-22							-
As at 31st March, 2022							29,70,01,900.00

B. Other Equity							Amount in Rs.
Particulars	Share application Pending Allotment	Reserve and Surplus				Other Comprehensive Income	Total
		Securities Premium Account	Share Based Payments Reserve Account	General reserve	Retained Earnings		
<b>As on 31 March 2021</b>							
Balance at the beginning of the reporting period i.e. 1st April, 2020	-	-	-	-	29,02,738.77	70,26,563.05	99,29,301.82
Profit for the year	-	-	-	-	9,01,958.00	-	9,01,958.00
Derecognition of Financial Asset	-	-	-	-	-	59,604.00	59,604.00
Other Comprehensive Income for the year	-	-	-	-	-	3,75,486.02	3,75,486.02
<b>Total Comprehensive Income for the year</b>	-	-	-	-	9,01,958.00	4,35,090.02	13,37,048.02
Balance at the end of the reporting period i.e. 31st March, 2021	-	-	-	-	38,04,696.77	74,61,653.07	1,12,66,349.84
<b>As on 31 March 2022</b>							
Balance at the beginning of the reporting period i.e. 1st April, 2021	-	-	-	-	38,04,696.77	74,61,653.07	1,12,66,349.84
Profit for the year	-	-	-	-	9,37,757.32	-	9,37,757.32
Derecognition of Financial Asset	-	-	-	-	-	-	-
Other Comprehensive Income for the year	-	-	-	-	-	(6,36,733.53)	(6,36,733.53)
<b>Total Comprehensive Income for the year</b>	-	-	-	-	9,37,757.32	(6,36,733.53)	3,01,023.79
Balance at the end of the reporting period i.e. 31st March, 2022	-	-	-	-	47,42,454.09	68,24,919.54	1,15,67,373.63

For S. N. Chakrabarty & Co.	CIN: L24232AS1987PLC002803
Firm Registration No. 309080E	For and on behalf of the Board of Directors
Chartered Accountants	
	Sd/-
	Sd/-
Saurindra Nath Chakrabarty	Swapan Sarkar
(Proprietor)	Director
MRN: 016230	DIN : 05149442
	Sandip Kumar Singh
	Director
	DIN : 08443518
Place: Kolkata	Sd/-
Date : 27th May, 2022	Sonam Agarwal
UDIN : 22016230AIRYH54256	Secretary
	ACS 55819

**Jagadishwar Pharmaceutical Works Limited**

Schedule 3 Tangible Assets

The previous year figures have been regrouped / reclassified, wherever necessary to conform to the current year presentation

Sl. No.	Particulars	Gross block							Depreciation and amortisation							Net block					
		As at April 1, 2020	Impact on IND AS Transition	Additions/ Adjustment	Deletions/ Adjustment	As at April 1, 2021	Additions/ Adjustment	Deletions/ Adjustment	As at Mar 31, 2022	As at April 1, 2020	Impact on IND AS Transition	Additions/ Adjustment	Impairment Loss	Deletions/ Adjustment	As at April 1, 2021	For the year	Deletions/ Adjustment	As at Mar 31, 2022	As at Mar 31, 2021	As at Mar 31, 2021	As at April 1, 2020
	Tangible Assets																				
1	Plant & Machinery	33,15,320.00		-	-	33,15,320.00	-	-	33,15,320.00	33,15,320.00		-	-	-	33,15,320.00	-	-	33,15,320.00	-	-	-
	<b>Total (A)</b>	<b>33,15,320.00</b>	-	-	-	<b>33,15,320.00</b>	-	-	<b>33,15,320.00</b>	<b>33,15,320.00</b>	-	-	-	-	<b>33,15,320.00</b>	-	-	<b>33,15,320.00</b>	-	-	-

## Jagadishwar Pharmaceutical Works Limited

### Schedule 4: Investments

Particulars	31 March, 2022		31 March, 2021		1 April, 2020	
	No. of Shares	Amount	No. of Shares	Amount	No. of Shares	Amount
Investment In Equity Instruments:						
Equity Shares		12,95,94,147.54		13,02,30,881.07		17,20,00,311.55
<b>Total :</b>		<b>12,95,94,147.54</b>		<b>13,02,30,881.07</b>		<b>17,20,00,311.55</b>

### Schedule 4.1

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
<b>Category-wise Non current</b>			
Financial assets carried at Amortised Cost			
Financial assets measured at Cost	-	-	-
Financial assets measured at Fair Value Through Other Comprehensive Income	12,95,94,147.54	13,02,30,881.07	17,20,00,311.55
Financial assets measured at Fair value Through Profit & Loss			
<b>Total :</b>	<b>12,95,94,147.54</b>	<b>13,02,30,881.07</b>	<b>17,20,00,311.55</b>

### Schedule 5: Other Non Current Assets

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
TDS Receivable	4,15,021.00	2,47,369.00	2,25,870.00
<b>Total :</b>	<b>4,15,021.00</b>	<b>2,47,369.00</b>	<b>2,25,870.00</b>

### Schedule 6: Inventories

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
Trading Shares	4,30,28,802.04	4,29,09,773.80	7,93,21,343.80
<b>Total :</b>	<b>4,30,28,802.04</b>	<b>4,29,09,773.80</b>	<b>7,93,21,343.80</b>

### Schedule 7: Cash & Cash Equivalents

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
Cash on hand	7,95,997.53	6,97,187.53	4,08,557.53
Balances with banks			
In Current Accounts	56,74,984.12	1,33,072.04	1,54,332.54
<b>Total :</b>	<b>64,70,981.65</b>	<b>8,30,259.57</b>	<b>5,62,890.07</b>

### Schedule 8: Loans (Current Assets)

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
Unsecured and Considered Doubtful Loans	4,76,97,794.00	7,17,82,439.00	2,65,05,999.00
<b>Total :</b>	<b>4,76,97,794.00</b>	<b>7,17,82,439.00</b>	<b>2,65,05,999.00</b>

### Schedule 9: Other Current Assets

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
Other Advances	6,22,84,541.40	4,31,89,541.40	92,39,541.40
Advance for Property	1,90,87,746.00	1,90,87,746.00	1,90,87,746.00
<b>Total :</b>	<b>8,13,72,287.40</b>	<b>6,22,77,287.40</b>	<b>2,83,27,287.40</b>

**Jagadishwar Pharmaceutical Works Limited**

**Schedule 10: Share Capital**

Particulars	As at 31 March, 2022		As at 31 March, 2021		As at 1 April, 2020	
	Number of shares	Rs.	Number of shares	Rs.	Number of shares	Rs.
<b>(a) Authorised</b> Equity Shares of Rs.10 each with voting rights	2,97,50,000	29,75,00,000.00	2,97,50,000	29,75,00,000.00	2,97,50,000	29,75,00,000.00
<b>(b) Issued, Subscribed and Paid - up</b> Equity Shares of Rs.10 each with voting rights	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00
<b>Total :</b>	<b>2,97,00,190</b>	<b>29,70,01,900.00</b>	<b>2,97,00,190</b>	<b>29,70,01,900.00</b>	<b>2,97,00,190</b>	<b>29,70,01,900.00</b>

**10.1 Rights, Preference and Restriction attached to shareholders**

Equity Shares : The Company has one class of equity shares having a par value of Rs. 10 per Share. Each Shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholder are eligible to receive the remaining assets of the company after distribution of all preferential amounts in proportion to their shareholding.

**10.2 Details of shares held by each shareholder holding more than 5% shares:**

Class of shares / Name of shareholder	As at 31 March, 2022		As at 31 March, 2021		As at 1 April, 2020	
	Number of shares held	%holding in that class of shares	Number of shares held	%holding in that class of shares	Number of shares held	%holding in that class of shares
Equity Shares with voting rights GROWDRE FUND MANAGEMENT CO. LIMITED	16,18,000	5.45	16,18,000	5.45	16,18,000	5.45
	<b>16,18,000</b>	<b>5.45</b>	<b>16,18,000</b>	<b>5.45</b>	<b>16,18,000</b>	<b>5.45</b>

**10.3 Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:**

Particulars	Number of shares	Rs.	Number of shares	Rs.	Number of shares	Rs.
Opening Balance	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00
Change during the year	-	-	-	-	-	-
Closing Balance	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00	2,97,00,190	29,70,01,900.00

**Schedule 11: Other Equity**

	Reserves & Surplus					
	Share Application Pending Allotment	Securities Premium Account	General reserve	Retained earnings	Other Comprehensive Income	Total
<b>As on 31 March 2021</b>						
Balance at the beginning of the reporting period i.e. 1st April, 2020	-	-	-	29,02,738.77	70,26,563.05	99,29,301.82
Profit for the year	-	-	-	9,01,958.00	-	9,01,958.00
Derecognition of Financial Asset	-	-	-	-	59,604.00	59,604.00
Other Comprehensive Income for the year	-	-	-	-	3,75,486.02	3,75,486.02
<b>Total Comprehensive Income for the year</b>	-	-	-	<b>9,01,958.00</b>	<b>4,35,090.02</b>	<b>13,37,048.02</b>
Balance at the end of the reporting period i.e. 31st March, 2021	-	-	-	38,04,696.77	74,61,653.07	1,12,66,349.84
<b>As on 31 March 2022</b>						
Balance at the beginning of the reporting period i.e. 1st April, 2021	-	-	-	38,04,696.77	74,61,653.07	1,12,66,349.84
Profit for the year	-	-	-	9,37,757.32	-	9,37,757.32
Derecognition of Financial Asset	-	-	-	-	-	-
Other Comprehensive Income for the year	-	-	-	-	(6,36,733.53)	(6,36,733.53)
<b>Total Comprehensive Income for the year</b>	-	-	-	<b>9,37,757.32</b>	<b>(6,36,733.53)</b>	<b>3,01,023.79</b>
Balance at the end of the reporting period i.e. 31st March, 2022	-	-	-	47,42,454.09	68,24,919.54	1,15,67,373.63

**Schedule 12: Other Financial Liabilities**

Particulars	As at 31 March, 2022 Rs.	As at 31 March, 2021 Rs.	As at 1 April, 2020 Rs.
Unsecured Borrowings			
i) Loan from Others	-	-	-
<b>Total :</b>	<b>-</b>	<b>-</b>	<b>-</b>

**Schedule 13: Other Current Liabilities**

Particulars	As at 31 March, 2021 Rs.	As at 31 March, 2020 Rs.	As at 1 April, 2019 Rs.
Outstanding Liabilities			
Liability for Expenses	9,000.00	9,000.00	12,500.00
Taxes Payable	-	-	-
Profession Tax Payable	760.00	760.00	-
<b>Total :</b>	<b>9,760.00</b>	<b>9,760.00</b>	<b>12,500.00</b>



**Jagdishwar Pharmaceutical Works Limited**

**Schedule 14: Revenue from Operations**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
i) Sale of Products		
Sale of Shares	1,84,500.00	3,50,80,085.00
<b>Total :</b>	<b>1,84,500.00</b>	<b>3,50,80,085.00</b>

**Schedule 15: Other Income**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
i) Interest	50,61,221.00	56,54,386.00
ii) Interest on I.T Refund	-	5,530.00
<b>Total :</b>	<b>50,61,221.00</b>	<b>56,59,916.00</b>

**Schedule 16: Changes in Inventory of Finished Goods**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
Opening Stock	4,29,09,773.80	7,93,21,343.80
Less: Closing Stock	4,30,28,802.04	4,29,09,773.80
<b>Increase / (Decrease) in Stocks</b>	<b>1,19,028.24</b>	<b>(3,64,11,570.00)</b>

**Schedule 17: Employee Benefits Expenses**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
Salary	19,15,398.00	14,47,500.00
Staff Welfare Expenses	1,03,790.00	71,990.00
<b>Total :</b>	<b>20,19,188.00</b>	<b>15,19,490.00</b>

**Schedule 18: Other Expenses**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
Advertisement	-	73,500.00
Annual Listing Fees	1,06,200	1,06,200.00
Auditors Remuneration	9,000	9,000.00
Bank Charges	88	737.50
CDSL Fees	88,500	88,500.00
Conveyance Expenses	1,01,000	73,970.00
E - Voting Expenses	62,740	60,380.00
Filing Fees	4,800	1,200.00
General Expenses	86,980	47,140.00
Interest on late payment of TDS	25,570	-
Loss on Sale of Shares	-	52,545.50
NSDL Fees	88,500	88,500.00
Penalty to MSEI	6,84,400	-
Postage	69,050	44,240.00
Printing & Stationery	1,36,268	68,540.00
Professional Charges	1,14,100	1,18,150.00
Profession Tax	2,500	2,500.00
Registrar Fees	11,800	11,800.00
Rent & Electricity	36,000	36,000.00
Telephone Expenses	49,970	38,310.00
Travelling Expenses	88,340	1,11,690.00
<b>Total :</b>	<b>17,65,805.92</b>	<b>10,32,903.00</b>

**18.1 Provision For Audit Fees**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
Statutory Audit Fees	9,000.00	9,000.00
	-	-
<b>Total :</b>	<b>9,000.00</b>	<b>9,000.00</b>

**Schedule 19: OCI- Items that will not form part of Profit/Loss**

Particulars	For the Year Ending March' 2022 Rs	For the Year Ending March' 2021 Rs
i. Change in Fair Value of Investments		
On reclassification of Financial Assets at Fair Value		
Other Comprehensive Income	(6,36,733.53)	4,35,090.02

<b>Jagadishwar Pharmaceutical Works Limited</b>					
<b>Notes on Financial Statements</b>					
<b>19. Related Party Disclosures</b>					
i. <u>As per Ind AS 24, the disclosures of transactions with Related Parties are given below:</u>					
List of related parties where control exists and related parties with whom transactions have taken place and relationships:					
<b>a) List of Related Parties</b>					
<b>i. Key Management Personnel</b>					
Sandip Kumar Singh					
Swapan Sarkar					
Gunodhar Ghosh					
Soma Ghosh					
Tulika Paul					
<b>b) Transactions undertaken / balances outstanding with related parties in the ordinary course of business</b>					
NI					

**JAGADISHWAR PHARMACEUTICAL WORKS LIMITED**

CIN: L24232AS1987PLC002803  
REGD. OFFICE: 205, Haribol Roy Market, 2<sup>nd</sup> Floor,  
A.T. Road, Guwahati – 781 001  
Website: www.jagadishwarpharma.com  
Email Id: jpw ltd@yahoo.com, Phone: +91 9163513015

**Form No. MGT-12  
Polling Paper**

*[Pursuant to section 109(5) of the Companies Act, 2013 and rule 21(1)(c) of the Companies  
(Management and Administration) Rules, 2014]*

Name of the Company :	<b>JAGADISHWAR PHARMACEUTICAL WORKS LIMITED</b>
Registered office :	205, Haribol Roy Market, 2 <sup>nd</sup> Floor, A.T. Road, Guwahati – 781 001

<b>BALLOT PAPER (34<sup>th</sup> AGM, 2022)</b>				
<b>S. No.</b>	<b>Particulars</b>	<b>Details</b>		
1.	Name of the First Named Shareholder (In block letters)			
2.	Postal address			
3.	Registered folio No. / *Client ID No. (*Applicable to investors holding shares in dematerialized form)			
4.	Class of Share	<b>Equity Share</b>		
I hereby exercise my vote in respect of Ordinary/ Special resolution enumerated below by recording my assent or dissent to the said resolution in the following manner:				
<b>S. No.</b>	<b>Resolutions</b>	<b>No. of shares held by me</b>	<b>I assent to the resolution</b>	<b>I dissent from the resolution</b>
1.	Adoption of Financial Statements for the financial year ended March 31, 2022:			
2.	Re-Appointment of Mr. Swapan Sarkar (holding DIN : 05149442) as a Director, liable to retire by rotation, who had offered himself for re-appointment:			

Place:

Date :

(Signature of the shareholder)

**BOOK POST**

***If undelivered return to :***

**JAGADISHWAR PHARMACEUTICAL WORKS LIMITED**

**Corp. Office: 21/7, Sahapur Colony, Ground Floor, Kolkata - 700053**